Signalling its intention to focus on the orphan drug space, Horizon Pharma has signed a deal worth approximately US$800 M to acquire rare disease specialist Raptor Pharmaceuticals. The acquisition will diversify the company’s growing orphan drug business with the addition of Procysbi®(cysteamine bitartrate delayed-release) and Quinsair™(levofloxacin), which are approved for nephropathic cystinosis and chronic pulmonary infection in cystic fibrosis, respectively. The deal will also increase Horizon’s geographic footprint and reduce its dependence on the primary care market.